Delisting from a major exchange like Nasdaq is a significant negative event for a company. It often leads to a decrease in the stock's liquidity and can negatively impact its price. The fact that Infinity Pharmaceuticals is not planning to request a review of the decision suggests that it may not have the means or the strategy to meet Nasdaq's listing requirements.